CytRx Corp said its experimental cancer drug improved survival rates in soft tissue sarcoma patients without the disease progressing, compared to chemotherapy alone, sending its shares up 75 percent before the bell.
The mid-stage trial tested the drug, aldoxorubicin, against a chemotherapy drug, doxorubicin, in 123 patients.
Help employers find you! Check out all the jobs and post your resume.
